Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, pharmacokinetics, and pharmacodynamics of CHF5074 in healthy young male subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CHF5074

Snippet

Sponsor: CERESPIR | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED